However, nothing has been presented to Biogen's board for consideration recently and one reason for this is that Biogen would expect a premium price on any proposal due to its perceived value of its neurology drugs portfolio, said the source.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.